This is evident from a large number of findings showing that EPLIN is downregulated across various malignancies, including oral cancer [6], breast cancer [7,41], prostate cancer [42,43,44,45], lung cancer [15,46], and ovarian cancer [47]. The gene discussed is LIMA1; the disease is prostate carcinoma.